目的 观察达那唑栓治疗子宫内膜异位症的疗效及不良反应。方法 选择曾行开腹或腹腔镜手术确诊的子宫内膜异位症再次复发患者87例，随机单盲分为两组，其中达那唑栓组46例，第一个月每晚2粒，之后每晚1粒，阴道或肛门用药，疗程6个月。达那唑胶囊对照组41例，口服给药，2次/d，疗程6个月，定期随访。比较应用达那唑栓及达那唑胶囊治疗子宫内膜异位症的症状、体征变化及不良反应情况。结果 达那唑栓组痛经、非经期下腹痛、性交痛、后陷凹结节、肛门坠痛的改善率与达那唑胶囊组比较，差异均无统计学意义（P＞0.05）。达那唑栓组体质量改变、转氨酶升高、阴道异常出血、闭经及痤疮不良反应发生率显著低于达那唑胶囊组，差异有统计学意义（P＜0.05）。结论 达那唑栓治疗复发性子宫内膜异位症与达那唑胶囊疗效相当，但不良反应较达那唑胶囊明显减少，安全性高。

Objective To observe the efficacy and adverse reactions of Danazol Suppository (DS) in the treatment of recurrent endometriosis. Methods Eighty-seven patients with recurrent endometriosis diagnosed by open and laparoscopic operation were randomly single-blind divided into two groups. DS group with 46 cases was administrated with two pills in the first month every evening and then one pill every evening via vaginal or anal administration, and the course was six months. The control group with 41 cases was po administrated with Danazol Capsule (DC) twice daily, for six months and regular follow-up. The symptoms, physical signs, and adverse reactions of DS and DC in the treatment of recurrent endometriosis were observed and compared. Results There were no significant differences in the improvement rates of dysmenorrhea, lower abdominal pain in non menstrual, the pain during pareunia and after excavation nodules, and rectal pain between DS and DC groups (P >0.05). But in DS group, the incidence of body weight change, elevated transaminases, abnormal vaginal bleeding, amenorrhea, and acne adverse reaction was significantly lower than that in DC group (P<0.05). Conclusion The effect of DS in the treatment of recurrent endometriosis is similar to that of DC, but adverse reactions are significantly decreased compared with DC,in high security.